Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension

Bin Liu1,2, Yi Peng3,4,5, Dan Yi1,2, Narsa Machireddy3,4,5, Daoyin Dong3,4,5, Karina Ramirez1,2, Jingbo Dai3,4,5, Rebecca Vanderpool6, Maggie M. Zhu3,4,5, Zhiyu Dai1,2,10 and You-Yang Zhao3,4,5,7,8,9,10

1Division of Pulmonary, Critical Care and Sleep, Dept of Internal Medicine, University of Arizona, Phoenix, AZ, USA. 2Translational Cardiovascular Research Center, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA. 3Program for Lung and Vascular Biology, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA. 4Section for Injury Repair and Regeneration Research, Stanley Manne Children’s Research Institute, Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA. 5Division of Critical Care, Dept of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 6Division of Medicine Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH, USA. 7Dept of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 8Dept of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 9Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 10Zhiyu Dai and You-Yang Zhao contributed equally to this article as lead authors and supervised the work.

Corresponding author: You-Yang Zhao (Youyang.zhao@northwestern.edu)

Shareable abstract (@ERSpublications)
Endothelial PHD2 deficiency decreases caveolin-1 expression leading to augmented nitrative stress, which contributes to obliterative pulmonary vascular remodelling and severe pulmonary hypertension https://bit.ly/3yw48zm

Cite this article as: Liu B, Peng Y, Yi D, et al. Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension. Eur Respir J 2022; 60: 2102643 [DOI: 10.1183/13993003.02643-2021].

Abstract

Background Nitrative stress is a characteristic feature of the pathology of human pulmonary arterial hypertension. However, the role of nitrative stress in the pathogenesis of obliterative vascular remodelling and severe pulmonary arterial hypertension remains largely unclear.

Method Our recently identified novel mouse model (Egln1Tie2Cre, Egln1 encoding prolyl hydroxylase 2 (PHD2)) has obliterative vascular remodelling and right heart failure, making it an excellent model to use in this study to examine the role of nitrative stress in obliterative vascular remodelling.

Results Nitrative stress was markedly elevated whereas endothelial caveolin-1 (Cav1) expression was suppressed in the lungs of Egln1Tie2Cre mice. Treatment with a superoxide dismutase mimetic, manganese (III) tetakis (1-methyl-4-pyridyl) porphyrin pentachloride or endothelial Nos3 knockdown using endothelial cell-targeted nanoparticle delivery of CRISPR–Cas9/guide RNA plasmid DNA inhibited obliterative pulmonary vascular remodelling and attenuated severe pulmonary hypertension in Egln1Tie2Cre mice. Genetic restoration of Cav1 expression in Egln1Tie2Cre mice normalised nitrative stress, reduced pulmonary hypertension and improved right heart function.

Conclusion These data suggest that suppression of Cav1 expression secondary to PHD2 deficiency augments nitrative stress through endothelial nitric oxide synthase activation, which contributes to obliterative vascular remodelling and severe pulmonary hypertension. Thus, a reactive oxygen/nitrogen species scavenger might have therapeutic potential for the inhibition of obliterative vascular remodelling and severe pulmonary arterial hypertension.

Introduction

Pulmonary arterial hypertension (PAH) is a devastating disease characterised by persistent increase of pulmonary vascular resistance and obstructive pulmonary vascular remodelling, which lead to right-sided heart failure and premature death [1–3]. Histopathological features of PAH from different aetiologies include increased vessel wall thickness, vascular fibrosis, augmented oxidative/nitrative stress, microvascular occlusion and complex plexiform lesions [4, 5]. Given that the molecular mechanisms of obliterative pulmonary vascular remodelling are not fully understood, current PAH therapies that mainly
target vasoconstriction, with little effect on vascular remodelling, are not effective in curing the disease and promoting survival [6, 7].

There is accumulating evidence of oxidative and/or nitrative stress in the lungs of patients with idiopathic PAH (IPAH). Xanthine oxidase activity involved in the generation of superoxide anions (reactive oxygen species (ROS)) is markedly increased in IPAH lungs [8], and they contribute to chronic hypoxia-induced pulmonary hypertension (PH) [9]. NADPH oxidases, including Nox1, Nox2 and Nox4, which also produce high levels of ROS, are also involved in the development of PH [10]. Staining by 8-hydroxyguanosine (a biomarker of oxidative damage caused by the reaction of superoxide with guanine) is prominent in endothelial cells (ECs) within the plexiform lesions of IPAH patients [11]. By contrast, the activity of antioxidants such as manganese superoxide dismutase (MnSOD), a key mitochondrial antioxidant enzyme coded by the SOD2 gene, was lower in IPAH lungs [11, 12]. Excessive production of nitric oxide (NO) and superoxide leads to formation of the damaging reactive nitrogen species (RNS) peroxynitrite [13, 14]. Elevated levels of peroxynitrite (i.e. nitrative stress) are detrimental, and can induce cell damage and death of pulmonary vascular cells, including ECs and smooth muscle cells (SMCs) [10, 15]. In addition, peroxynitrite modifies tyrosine residue, resulting in tyrosine nitration of proteins (formation of 3-nitrotyrosine) and thus modification of their functions [13, 14, 16]. Peroxynitrite levels are elevated in the lungs of IPAH patients [11, 12], in part due to tissue hypoxia and inflammation [15]. Immunohistochemical staining shows ubiquitous 3-nitrotyrosine and a marked increase in its levels [11]. Our previous studies showed that caveolin-1 (Cav1) deficiency results in endothelial nitric oxide synthase (eNOS) activation and a marked increase in NO levels, as well as augmented production of superoxide, which form peroxynitrite leading to prominent nitrative stress in pulmonary vasculature [16, 17]. The resultant augmentation of nitrative stress causes protein kinase G (PKG) tyrosine nitration, which impairs its kinase activity, leading to enhanced vasoconstriction and vascular remodelling and thus PH as seen in Prkg1−/− mice (Prkg encodes PKG) [16, 18, 19]. PKG tyrosine nitration is markedly increased in the lungs of IPAH patients [16].

We recently reported a new mouse model of severe PH (Tie2Cre-mediated disruption of Egln1, encoding hypoxia-inducible factor (HIF) prolyl hydroxylase 2 (PHD2), designated as Egln1^{Tie2Cre} (CKO)) with progressive obliterator vascular remodelling including vascular occlusion, plexiform-like lesions and right heart failure, which recapitulates many features of clinical PAH including IPAH [20, 21]. However, it is unknown whether oxidative/nitrative stress is also augmented and involved in the pathogenesis of PH in this severe PH model. In the present study, we for the first time demonstrate that endothelial PHD2 deficiency induces extensive oxidative/nitrative stress via downregulation of endothelial Cav1 expression in a HIF-2α-dependent manner. ROS scavenger treatment, genetic disruption of EC-specific Nos3 or restoration of Cav1 expression markedly decreased nitrative stress and attenuated PH in CKO mice.

Methods

Animal models

All the mice used in this study are C57BL/6J background. Egln1^{Tie2Cre} (CKO) and Hif2a/Egln1^{Tie2Cre} (EH2) mice were generated as described previously [20]. Cav1^{18} mice were obtained from Dr William Sessa’s laboratory (Yale University, New Haven, CT, USA) [22, 23]. CKO mice were bred with Cav1^{18} mice to generate Egln1^{Tie2Cre}/Cav1^{18} (CKO/Tg) and Egln1^{Tie2Cre}/Cav1^{18} (Tg) mice. Male and female Egln1^{H2} (designated as wild type (WT)), CKO, CKO/Tg and Tg littermates at age 5 weeks to 3.5 months were used in these studies. For ROS scavenger treatment, male and female CKO mice at age 5 weeks were treated with manganese (III) tetras (1-methyl-4-pyridyl) porphyrin pentachloride (MnTMPyP) (5 mg·kg⁻¹) [16] intraperitoneally daily for 9 weeks. PBS was used as a control. The same PBS group was used in our previous publication [24]. The animal care and study protocols were reviewed and approved by the Institutional Animal Care and Use Committees of Northwestern University Feinberg School of Medicine, and the University of Arizona.

Echocardiography

Echocardiography was performed in the Core facilities at Northwestern University Feinberg School of Medicine and the University of Arizona as described previously [20, 25, 26]. Transthoracic echocardiography was performed on a VisualSonics Vevo 2100 or 3100 ultrasound machine (FujiFilm VisualSonics Inc.) using an MS550D (40 MHz) transducer. Right ventricle (RV) wall thickness during diastole was obtained from the parasternal short axis view at the papillary muscle level using M-mode. The RV cross-sectional area was obtained from the parasternal short axis view at the papillary muscle level using B-mode. Pulmonary artery (PA) acceleration time and PA ejection time were obtained from the parasternal short axis view at the aortic valve level using pulsed Doppler mode. Left ventricular (LV)
FIGURE 1 Augmented nitrative stress in pulmonary vascular lesions in Egln1Tie2Cre (CKO) mice. a) 2′, 7′-dichlorodihydrofluorescein (DCF) measurement demonstrating marked increase of reactive oxygen species (ROS)/reactive nitrogen species (RNS) in the lungs of CKO mice. Lung tissue was collected from 3.5-month-old wild type (WT) and CKO mice for DCF assay. b, c) Western blotting demonstrating increase of nitrotyrosine expression in CKO mice compared to WT. d, e) Immunofluorescence staining showing CD31 and CD45 expression in WT and CKO mice.
fractional shortening and the cardiac output were obtained from the parasternal short axis view using M-mode.

**Haemodynamic measurements**
To measure right ventricular systolic pressure (RVSP), mice were anaesthetised with a ketamine/xylazine cocktail. A 1.4 F pressure transducer catheter (Millar Instruments) was inserted through the right jugular vein into the RV. RVSP was recorded and analysed by AcqKnowledge software (Biopac Systems Inc.) as described previously [20, 25, 26].

**EC isolation**
Mouse lung tissues were well perfused with PBS to remove blood. The tissues were then minced and incubated with collagenase A (1.0 mg·mL$^{-1}$ in HBSS, Roche) in a shaking water bath at 37°C for 45 min, and then were dispersed by gentleMACS Dissociator (Miltenyi Biotec), followed by filtering through a 40 μm cell strainer. Cells were then incubated with anti-mouse CD31 antibody (BD Biosciences, Cat#550274, 1.5 μg·mL$^{-1}$) on ice for 1 h, followed by incubation with sheep anti-rat IgG Dynabeads M-450 (Invitrogen, Cat#11035, 50 μL) for 30 min. Bead-bound ECs (CD31$^+$ cells) were pulled down by magnetism and lysed for protein isolation [25, 26].

**Histological assessment**
Mouse lung tissues were perfused with PBS, fixed with 10% formalin via tracheal instillation at a constant pressure (15 cmH$_2$O) and embedded in paraffin wax. Lung sections were stained with a Russell–Movat pentachrome staining kit (American MasterTech) according to the manufacturer’s protocols. For assessment of PA wall thickness, PAs from 40 images at ×20 magnification were quantified by Image J. Wall thickness was calculated by the distance between the internal wall and external wall divided by the distance between the external wall and centre of the lumen [20, 25, 26].

**Immunofluorescent staining**
Mouse lung tissues were perfused with PBS, inflated with 50% optimal cutting temperature (OCT) compound in PBS and embedded in OCT for cryosectioning. For immunofluorescent staining of Cav1 and α-nitrotyrosine (NT) [16], lung sections (5 μm) were fixed with 4% paraformaldehyde and blocked with 0.1% Triton X-100 and 5% normal goat serum at room temperature for 1 h. After three washes with PBS, the slides were incubated with anti-Cav1 (Santa Cruz Biotechnology, Cat#ab-894, 1:100), anti-NT (Millipore, Cat#ab-233,1:300), anti-CD31 antibody (BD Bioscience, Cat#550274, 1:25), anti-α-smooth muscle actin (α-SMA) (Abcam, Cat#ab-5694, 1:300), anti-CD45 (BioLegend, Cat#ab-103101, 1:100) or anti-periostin (Abcam, Cat#ab-14041, 1:100) at 4°C overnight followed by Alexa 594-conjugated or 488-conjugated anti-rabbit IgG at room temperature for 1 h. Nuclei were counterstained with DAPI and images were taken using Zeiss Confocal microscope LSM880 and tiled scanning at ×20 magnification. Images were taken using the Zeiss Confocal microscope LSM880 and tiled scanning at ×20 magnification. α-SMA$^+$ vessels were quantified in 40 fields per lung [20, 25, 26].

**RNA isolation and quantitative reverse transcriptase PCR analysis**
One lobe of lung tissue was homogenised by a TissueLyser (Qiagen) in Trizol solution (Life Technology). RNA was isolated by phenol:chloroform, followed by clean-up with Qiagen RNeasy mini kit (Qiagen). A high-capacity cDNA reverse transcription kit (Applied Biosystems) was used to transcribe 1 μg of RNA into cDNA. Quantitative reverse transcriptase PCR (RT-PCR) analysis was performed on an ABI ViiA 7 Real-Time PCR System (Applied Biosystems) with the FastStart SYBR Green Master kit (Roche Applied Science). Target mRNA expression was determined using the comparative cycle threshold method of
FIGURE 2 MnTMPyP (Mn) treatment reduced pulmonary hypertension in Egln1Tie2Cre (CKO) mice.  

a) Immunostaining against nitrotyrosine (NT) showed that Mn treatment reduced NT modification in CKO lungs. CKO mice aged 5 weeks were treated with either Mn or PBS for 9 weeks. Scale bars: 50 μm.  
b, c) Right ventricular systolic pressure (RVSP) was measured and right ventricular (RV) hypertrophy determined in 3.5-month-old CKO mice after 9 weeks of treatment with Mn or PBS. Egln1f/f (wild type (WT)) mice were used as controls. RVSP and RV hypertrophy were also
determined in 5-week-old CKO mice (5W) without treatment. d, e) Mn treatment inhibited neointima formation and decreased pulmonary artery (PA) wall thickness. Lung sections were processed for Russell–Movat pentachrome staining. f, g) Quantification of α-smooth muscle actin (α-SMA) immunostaining demonstrated decreased muscularisation of distal pulmonary vessels in Mn-treated CKO mice. Lung cryosections were immunostained with anti-α-SMA (red) and counterstained with DAPI (blue). Arrows point to muscularised distal pulmonary vessels. Statistical significance in b, c, e and g determined by one-way ANOVA with Tukey post hoc analysis. V: vessel. *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.

relative quantitation. Cyclophilin A was used as an internal control. Information for mouse Cav1 and cyclophilin A primers has been described previously [20]; mouse Nos3 primers were 5′-AGGCAATCTTC GTTCAGCCA-3′ and 5′-TAGCCCCGATAGCGTATCAG-3′.

**Immunoprecipitation and Western blotting**

Lung tissues were collected from 3.5-month-old mice for homogenisation. 500 µg of lysates per mouse were then immunoprecipitated with anti-PKG antibody [16] and protein conjugated-Sepharose beads and blotted with anti-NT antibody (Millipore, Cat#05-233, 1:2000). The same membrane was also blotted with anti-PKG antibody (Cell Signaling Technology, Cat#13511S, 1:1000) as a loading control. Other Western blotting assays were performed using anti-Cav1 (Santa Cruz Biotechnology, Cat#sc-894 or sc-53564, 1:2000), anti-NT (Millipore, Cat#05-233, 1:2000) or anti-eNOS (BD Biosciences, Cat#610297, 1:1000). Anti-β-actin (Sigma, Cat#A2228, 1:10 000) was used as a loading control.

**Measurement of ROS/RNS levels**

Lung tissues were perfused free of blood with PBS, followed by collection of the left lobe. 50 mg of lung tissue was homogenised in PBS on ice. Tissue homogenates were spun at 10 000 rpm for 10 min and extracted with a phenol:chloroform mixture followed by ethanol precipitation to isolate genomic DNA. SYBR Green-based quantitative PCR analysis of genomic DNA was carried out with the Quant Studio 6-Flex Real-Time PCR system (Applied Biosystems; SYBR Green from Roche Applied Science) to determine genome indel efficiency as described previously [27]. The sequences of the forward and reverse primers were 5′-CACGTAATCAGAGCT CTCAG-3′ and 5′-TAGCCCCGATAGCGTATCAG-3′.
FIGURE 3 Endothelial Nos3 knockdown attenuated pulmonary hypertension in Egln1FloxCre (CKO) mice. a) Quantitative reverse transcriptase PCR analysis demonstrating Nos3 mRNA expression is upregulated in CKO mouse lungs compared to wild type (WT) lungs and restored in Egln1FloxCre/Hif2αFloxCre (EH2) lungs. Lung tissue was collected from 3.5-month-old mice. b) Strategy for knockdown of endothelial Nos3 in CKO mice. A mixture of nanoparticles:CRISPR plasmid DNA was administered to CKO mice at age 7, 8 and 9 weeks to disrupt Nos3 expression in endothelial cells (ECs). c) Endothelial nitric oxide synthase (eNOS) protein and nitrotyrosine (NT) levels were markedly reduced in Nos3 guide RNA (gRNA) plasmid
DNA-treated CKO mice compared with control vector DNA-treated mice. d) Immunostaining against eNOS demonstrated that eNOS was reduced in the lung ECs of Nos3 gRNA plasmid DNA-treated CKO mice. Scale bars: 50 μm. e) Endothelial Nos3 knockdown attenuated NT levels in the lung ECs of CKO mice. Scale bars: 50 μm. f) Haemodynamic measurement showing that endothelial Nos3 knockdown attenuated right ventricular systolic pressure (RVSP) in CKO mice. g) Right ventricular hypertrophy (weight ratio of right ventricle/left ventricle plus septum (RV/(LV+S)) was reduced in endothelial Nos3 knockdown CKO mice. h, i) Endothelial Nos3 knockdown in CKO mice reduced neointima formation and decreased pulmonary artery (PA) wall thickness. Lung sections were processed for Russell–Movat pentachrome staining. Scale bars: 50 μm. j, k) Quantification of α-smooth muscle actin (α-SMA) immunostaining demonstrated decreased muscularisation of distal pulmonary vessels in endothelial Nos3 knockdown CKO mice. Lung cryosections were immunostained with anti-α-SMA (red) and counterstained with DAPI (blue). Arrows point to muscularised distal pulmonary vessels. Scale bars: 50 μm. Statistical significance in c, d, f and h determined by one-way ANOVA with Tukey post hoc analysis. V: vessel. *: p<0.05, **: p<0.01; ***: p<0.001; ****: p<0.0001.

5′-AATCCTCAGCCTATTGGCTGAC-3′. The primer sequences of the control Nme1 DNA were 5′-CCCC TTCTTACTGGCCTGG-3′ and 5′-GCTATCCACAGGCTGT TT-3′ for normalisation.

**Statistical analysis**

Statistical significance was determined by one-way ANOVA with a Tukey post hoc analysis that calculates p-values corrected for multiple comparisons. Two-group comparisons were analysed by unpaired two-tailed t-test. p<0.05 denoted the presence of a statistically significant difference. The data in all bar graphs is presented as mean±SD.

**Results**

### Prominent nitrative stress in Egln1Tie2Cre mouse lungs and pulmonary vascular ECs

Given that nitrative stress is a characteristic feature of the pathology of clinical PAH, we tested whether nitrative stress is also prominent in the lung of Egln1Tie2Cre (CKO) mice. Quantification of total free radical levels with the OxiSelect In Vitro ROS/RNS Assay Kit of lung homogenates showed that CKO lungs exhibited markedly elevated ROS/RNS levels (figure 1a). Western blotting demonstrated markedly increased levels of NT, indicative of nitrative stress, in CKO mouse lungs (figure 1b, c). We then performed NT immunostaining together with markers for ECs (CD31), inflammatory cells (CD45), fibroblasts (periostin) and SMCs (α-SMA) to determine which cell types were the NT+ cells in the CKO lungs. Our data showed that NT was highly expressed in the pulmonary vascular ECs and CD45+ inflammatory cells, with relatively low expression in pulmonary vascular SMCs and periostin+ fibroblasts (figure 1d, e and supplementary figure S1a, b). Our previous studies demonstrated that nitration-dependent impairment of PKG activity is involved in PH development [16]. To further determine whether PHD2 deficiency also affects PKG nitration, we performed an immunoprecipitation assay using anti-PKG antibody and blotted with anti-NT antibody. The data showed that PKG nitration was markedly increased in the lungs of CKO mice (supplementary figure S2). Together, these data suggest that nitrative stress is markedly augmented in the pulmonary vascular lesions in CKO mice.

### ROS scavenger treatment inhibited obliterative vascular remodelling and attenuated PH in Egln1Tie2Cre mice

We next determined whether depletion of ROS/RNS in CKO mice affected PH development. 5-week-old CKO mice with an established PH phenotype were treated intraperitoneally with the ROS/peroxynitrite scavenger MnTMPyP, which disrupts superoxide and thus peroxynitrite formation [16, 28], for 9 weeks. MnTMPyP treatment markedly reduced the levels of NT in the pulmonary vasculatures and lungs of CKO mice (figure 2a). Haemodynamic measurements showed that RVSP was reduced to ∼50 mmHg in MnTMPyP-treated CKO mice compared to ∼77 mmHg in PBS-treated CKO mice (figure 2b). RV hypertrophy, determined by the weight ratio of the RV versus left ventricle plus septum (LV+S), was also attenuated in MnTMPyP-treated CKO mice (figure 2c). An examination of lung pathology also revealed inhibition of occlusive vascular remodelling, evidenced by diminished neointima formation (figure 2d), and decreased PA wall thickness and muscularisation of distal pulmonary vessels in MnTMPyP-treated CKO mice compared to PBS-treated mice (figure 2e–g). Together, these data suggest the involvement of oxidative/nitrative stress in the development of severe PH in CKO mice.

### Nos3 knockdown in ECs reduces nitrative stress, vascular remodelling and severe PH in Egln1Tie2Cre mice

Peroxynitrite is formed by a reaction between NO and superoxide. To determine whether NO mediates nitrative stress and PH development in CKO mice, we treated CKO mice with a pan-inhibitor (Nω-nitro-L-arginine methyl ester (L-NAME)) of NO synthases in the drinking water (1 mg·mL−1); however, all seven CKO mice died within 1 week (data not shown), suggesting that NO bioavailability is...
Endothelial caveolin 1 (Cav1) expression was suppressed in Egln1^{Tie2Cre} (CKO) mouse lungs in a hypoxia-inducible factor 2α (HIF-2α)-dependent manner.  

**a)** Quantitative reverse transcriptase PCR analysis demonstrated decreased Cav1 mRNA expression in CKO mouse lungs compared to wild type (WT) lungs, which was restored in Egln1^{Tie2Cre}/Hif2a^{Tie2Cre} (EH2) lungs. Lung tissue was collected from 3.5-month-old mice.  

**b, c)** There was decreased Cav1 protein expression in CKO mouse lungs compared to WT lungs. Cav1 protein expression in EH2 mouse lungs was markedly increased compared to WT and CKO mouse lungs.  

**d)** Immunostaining demonstrated diminished Cav1 expression in pulmonary vascular endothelial cells of CKO mice and restoration in EH2 mice. Lung sections were immunostained with anti-Cav1 (red) and CD31 (green). Nuclei were counterstained with DAPI (blue). Scale bars: 50 μm. Statistical significance for a and c determined by one-way ANOVA with Tukey post hoc analysis. V: vessel. *: p<0.05; **: p<0.01; ***: p<0.001.
FIGURE 5 Caveolin 1 (Cav1) transgenic expression in Egln1Tie2Cre (CKO) mice. a) Strategy of generating Egln1Tie2Cre/Cav1Tg (CKO/Tg) mice by breeding Cav1 transgenic mice (Cav1Tg) into the genetic background of CKO mice. b) Western blotting demonstrating restored Cav1 expression in CKO/Tg mouse lungs. c) Immunostaining demonstrated that Cav1 expression was downregulated in lung endothelial cells of CKO mice compared to wild type (WT) and restored in CKO/Tg mice. Lung sections were immunostained with anti-Cav1 (red) and CD31 (green). Nuclei were counterstained with DAPI (blue). Scale bars: 50 μm. Statistical significance for b determined by one-way ANOVA with Tukey post hoc analysis. *: p<0.05; **: p<0.01; ****: p<0.0001.
**FIGURE 6** Caveolin 1 (Cav1) transgenic expression inhibited excessive reactive oxygen species (ROS)/reactive nitrogen species (RNS) in *Egln1<sup>Tie2Cre</sup>* (CKO) mouse lungs. 

**a)** 2', 7'-dichlorodihydrofluorescein (DCF) measurements demonstrating that the increased production of ROS/RNS seen in CKO mouse lungs was inhibited in *Egln1<sup>Tie2Cre</sup>/Cav1<sup>Tg</sup>* (CKO/Tg) mouse lungs. There was no marked difference in lung generation of ROS/RNS in *Egln1<sup>f/f</sup>/Cav1<sup>Tg</sup>* (Tg) mice compared to wild type (WT) mice. WT and CKO data shared with figure 1a. 

**b)** Western blotting demonstrated a reduction in nitrotyrosine (NT) levels in CKO/Tg mice compared to CKO mice. 

**c)** Representative immunostaining showed that CKO/Tg mice exhibited reduced...
NT levels compared to CKO mice. Lung sections were immunostained with anti-NT (red) and CD31 (green). Nuclei were counterstained with DAPI (blue). Scale bars: 50 μm. Statistical significance in a and b determined by one-way ANOVA with Tukey’s post hoc analysis. *: p<0.05; **: p<0.01; ****: p<0.0001.

Critical for the maintenance of vascular homeostasis in this severe PH model, Nos3 (encoding eNOS) but neither Nos1 nor Nos2 was upregulated in the CKO lungs (figure 3a and supplementary figure S3), and Nos3 normalised in lungs of Egln1 and Hif2a double knockout mice (Egln1\(^{Tie2Cre}\)/Hif2a\(^{Tie2Cre}\) (EH2)), suggesting that eNOS mediates nitrative stress in CKO mice. To investigate this, we leveraged nanoparticle delivery of CRISPR–Cas9 plasmid DNA [27] expressing Cas9 under the control of the CDH5 promoter and Nos3-specific gRNAs driven by the U6 promoter to specifically knockdown Nos3 in ECs of CKO mice (figure 3b). We observed ~30% genome editing efficiency in lung ECs of Nos3 gRNA plasmid DNA-treated CKO mice (supplementary figure S4), and diminished eNOS protein expression (figure 3c). Immunostaining also showed diminished eNOS expression in lung ECs of these mice compared with control mice (figure 3d), demonstrating successful knockdown of Nos3 in CKO lung ECs. Accordingly, NT levels were also markedly decreased in lung ECs of these Nos3 gRNA plasmid DNA-treated CKO mice (figure 3c, e). Haemodynamic measurements showed that Nos3 knockdown in ECs significantly reduced RVSP and RV/(LV+S) ratio in these CKO mice (figure 3f, g). Pulmonary vascular remodelling, assessed via PA wall thickness (figure 3h, i), and muscularisation of distal pulmonary vessels (figure 3j, k) were also markedly attenuated in these mice. Additionally, all five Nos3 gRNA plasmid DNA-treated mice survived, compared to 50% mortality in control CKO mice during the same period. These data demonstrate that eNOS is the primary source of nitrative stress, which contributes to the development of occlusive remodelling and severe PH seen in CKO mice.

**Decreased expression of endothelial Cav1 secondary to PHD2 deficiency in a HIF-2α-dependent manner**

Cav1 deficiency activates eNOS and increases ROS/RNS production, leading to nitrative stress, which post-translationally modifies PKG through tyrosine nitration and impairs its kinase activity, leading to PH [16, 19]. To find out whether dysregulation of Cav1 signalling is involved in the generation of nitrative stress and PH development in CKO mice, we first checked the expression level of Cav1 in the lungs of CKO mice. As shown in figure 4a, Cav1 mRNA levels were markedly decreased in the lungs of CKO mice compared to those in similar age WT mice. HIF-2α deletion in CKO (EH2) mice restored Cav1 mRNA expression (figure 4a). Western blotting also demonstrated reduced Cav1 protein levels in CKO lungs, which was reversed in EH2 mice and in fact increased in EH2 mouse lungs compared to WT lungs (figure 4b, c). By performing immunofluorescent staining, we found that Cav1 is co-stained with CD31+ cells (i.e. ECs) in the pulmonary vasculature of WT mice whereas it is diminished in pulmonary vascular lesions in CKO mice and restored in pulmonary vascular ECs of EH2 mice (figure 4d), suggesting that endothelial Cav1 is reduced by PHD2 deficiency dependent on HIF-2α activation in Egln1\(^{Tie2Cre}\)/Cav1\(^{Tg}\) mice.

**Restored Cav1 expression inhibited nitrative stress in Egln1\(^{Tie2Cre}\)/Cav1\(^{Tg}\) mice**

To determine whether Cav1 deficiency is responsible for the augmentation of nitrative stress via eNOS activation and the pathogenesis of PH in CKO mice, we generated a mouse model with Cav1 transgenic expression under control of the preproET-1 promoter in the genetic background of CKO mice (Egln1\(^{Tie2Cre}\)/Cav1\(^{Tg}\) (CKO/Tg)) [23]. Western blotting and immunostaining demonstrated that reduced Cav1 expression seen in CKO mouse lungs was restored in CKO/Tg mice (figure 5b, c). Restored Cav1 expression in CKO mice drastically reduced the levels of ROS/RNS in the lungs of CKO/Tg mice compared to CKO mice (figure 5a). Further examination of NT levels via Western blotting and immunostaining showed that NT levels were inhibited in the lung and pulmonary vascular ECs of CKO/Tg mice compared to CKO mice (figure 6b, c), suggesting that Cav1 deficiency is responsible for the increased oxidative/nitrative stress in CKO mouse lungs.

**Cav1 transgenic expression attenuates PH seen in Egln1\(^{Tie2Cre}\) mice**

We next determined if Cav1 transgenic expression in CKO mice would rescue the hypertensive pulmonary phenotype. Haemodynamic measurement demonstrated a partial decrease of RVSP in CKO/Tg at age 3.5 months compared to CKO mice (figure 7a). RV hypertrophy was also attenuated in CKO/Tg mice (figure 7b). Pathological examination showed that CKO/Tg mice had reduced pulmonary vascular remodelling, including decreases in neointima and occlusive lesions (figure 7c), PA wall thickness (figure 7d) and muscularisation of distal pulmonary vessels in comparison to CKO mice (figure 7e, f).
FIGURE 7 Transgenic expression of caveolin 1 (Cav1) inhibited severe pulmonary hypertension seen in Egln1Tie2Cre (CKO) mice. a, b) Egln1Tie2Cre/Cav1<sup>16</sup> (CKO/Tg) mice exhibited marked decreases of right ventricular systolic pressure (RVSP) (a) and right ventricular hypertrophy (weight ratio of right ventricle/left ventricle plus septum (RV/(LV+S)) (b) compared to CKO mice at age 3.5 months. c, d) Representative micrographs of Russell–Movat pentachrome staining showing inhibited obliterative vascular remodelling including diminished neointima formation and reduced pulmonary artery (PA) wall thickness in the lung of CKO/Tg mice. Scale bar: 50 μm. e, f) Immunostaining of α-smooth muscle actin (α-SMA) demonstrating inhibition of muscularisation of distal pulmonary vessels in the lungs of CKO/Tg mice. Arrows indicate muscularised pulmonary vessels. Statistical significance in a, b, d and f determined by one-way ANOVA with Tukey’s post hoc analysis. ***: p<0.001.
**Cav1 transgenic expression normalises RV and PA functions in Egln1\textsuperscript{Tie2cKO}/Cav1\textsuperscript{Tg} mice**

We next evaluated whether Cav1 transgenic expression inhibits the right heart dysfunction seen in CKO mice. Echocardiography showed that CKO/Tg mice had marked decreases of RV wall thickness compared to CKO mice (figure 8a–c). CKO/Tg mice also exhibited marked improvements of RV contractility assessed by RV fraction area change (figure 8d, and supplementary videos S1 and S2). However, we did not observe a significant change in heart rate, cardiac output or LV fractional shortening in CKO/Tg mice compared with CKO mice (supplementary figure S5a–c). CKO/Tg mice exhibited improved PA function, assessed by PA acceleration time/ejection time ratio, compared to CKO mice (figure 8e). These data demonstrate that Cav1 transgenic expression partially but significantly rescues the defective PA and RV functions seen in CKO mice.

**Discussion**

The present study demonstrated that nitrative stress was markedly augmented in the lungs, especially in vascular lesions of CKO mice, recapitulating the pathological feature of clinical PAH. Augmentation of nitrative stress was due to endothelial Cav1 deficiency and eNOS activation. Cav1 transgenic expression in CKO/Tg mice reduced nitrative stress levels and attenuated PH, evidenced by a reduction in RVSP, pulmonary vascular remodelling and RV hypertrophy, as well as improvements in RV and PA function. Both pharmacological scavenging of ROS/RNS and genetic knockdown of endothelial Nos3 via EC-targeted nanoparticle delivery of CRISPR–Cas9 technology in adult mice diminished nitrative stress and markedly reduced the severity of pulmonary vascular remodelling and PH in CKO mice. These findings suggest that restoration of Cav1 expression and ROS/RNS scavenging represent potential therapeutic strategies for the treatment of severe PAH, including IPAH (figure 8f). The clinical relevance is validated by our previous observation that PHD2 expression was diminished in ECs of occlusive pulmonary vessels in IPAH patients [20].

Prominent oxidative/nitrative stress is a pathological feature of clinical PAH [10, 15, 16]. Our recent study showed for the first time that CKO mice spontaneously develop severe PH with obliterative pulmonary vascular remodelling, including occlusive vascular lesions, formation of plexiform-like lesions and marked elevation of RVSP ranging from 70–100 mmHg as well as development of right heart failure [20]. Here we show a marked increase of ROS/RNS in CKO mouse lungs and prominent anti-NT staining indicative of extensive nitrative stress in pulmonary vascular lesions, especially in ECs and inflammatory cells. This study provides further evidence that CKO mice are an excellent mouse model of human PAH. Furthermore, treatment of the mice with the ROS scavenger MnTMPyP inhibited occlusive pulmonary vascular remodelling and attenuated PH, demonstrating the pathogenic role of oxidative/nitrative stress in the severity of PH.

Nitrative stress is created by excessive superoxide and NO, which chemically react to form peroxynitrite. We found that expression of Nos3 but neither Nos1 nor Nos2 was markedly increased in CKO lungs. To specifically inhibit peroxynitrite formation, we employed the EC-targeted nanoparticle delivery of CRISPR plasmid DNA technology to selectively disrupt Nos3 expression in ECs in adult CKO mice, which resulted in diminished nitrative stress in CKO lungs and especially in pulmonary vascular ECs. These data demonstrate that ECs are the primary sources of nitrative stress via eNOS expression and activation secondary to PHD2 deficiency in CKO lungs. Given that peroxynitrite is more stable and diffusible than NO, EC-derived nitrative stress can easily spread into other cell types in the lesions, such as pulmonary vascular SMCs, fibroblasts and infiltrated proinflammatory cells. Thus, EC-specific Nos3 knockdown results in decreased nitrative stress not only in ECs but also in whole lungs. Additionally, EC-derived peroxynitrite diffuses to pulmonary vascular SMCs and induces tyrosine nitration of PKG expressed in SMCs, which impairs its kinase activity, leading to pulmonary vascular remodelling and PH development. Consistently, we observed reduced RVSP, pulmonary vascular remodelling and RV hypertrophy in endothelial Nos3-disrupted CKO mice. Together, these data provide unequivocal evidence of nitrative stress derived from endothelial dysfunction contributing to obliterative pulmonary vascular remodelling and severe PH development.

Previous studies have shown decreases of CAV1 mRNA and protein levels in lung ECs of patients with PAH [16]. Cav1 deficiency is also evident in the arterial lesions of PH rats, including both the Sugen5416/ hypoxia-induced PH and monocrotaline-induced PH models [29, 30]. Our previous study provides the first genetic evidence that Cav1 deficiency induces PH in mice [17]. A recent study showed that Cav1 deficiency in ECs promotes more severe PH in response to hypoxia [31]. Consistently, CAV1 mutation is associated with heritable PAH in patients [32]. Together, these studies provide clear evidence of CAV1 deficiency in the pathogenesis of PH. Our other study has shown that genetic deletions of both Cav1 and Nos3 or treatment of Cav1\textsuperscript{−/−} mice with either NO synthase inhibitor L-NAME or ROS/RNS scavenger...
FIGURE 8 Caveolin 1 (Cav1) transgenic expression improved right heart and pulmonary artery (PA) functions in Egln1Tie2Cre/Cav1Tg (CKO/TG) mice. a) Representative echocardiography B-mode showing reduced right ventricle (RV) chamber size in CKO/Tg mice compared to Egln1Tie2Cre (CKO) mice. b) Representative echocardiography M-mode showing reduced RV wall thickness at diastolic stage in CKO/Tg mice compared to CKO mice. c) RV wall thickening seen in CKO mice was reduced in CKO/Tg mice. d) RV contractility as determined by fraction area change (FAC) was improved by restored endothelial Cav1 expression in CKO/Tg mice compared to CKO mice. e) PA AT/ET was also improved in CKO/Tg mice compared to CKO mice. f) Caveolin 1 (Cav1) stabilisation by Egln1Tie2Cre increased oxidative/nitrative stress in inflammatory and endothelial cells and prevented obliterative remodelling and severe pulmonary hypertension.
that L-NAME treatment inhibits PH in to Cav1 deficiency is the mechanism of PH induced by CAV1 deficiency [16]. Others have also shown secondary to Cav1 deficiency leads to peroxynitrite formation, which causes PKG nitration in mediated by endothelial Cav1 deficiency ascribed to HIF-2

In summary, we have demonstrated prominent nitrative stress in vascular lesions of CKO mice, which is In CKO mice, we observed elevated levels of ROS/RNS and PKG nitration and decreased endothelial Cav1 expression. We demonstrated that Cav1 deficiency in CKO mice is involved in the regulation of nitrative stress because Cav1 transgenic expression normalises the levels of ROS/RNS and inhibits nitrative stress, as evidenced by diminished NT levels in pulmonary vascular ECs, and thus inhibits obliterative pulmonary vascular remodelling and reduces PH as well as improves RV and PA function in CKO mice. We observed complete inhibition of occlusive vascular remodelling without neointima formation in CKO/Tg mice, endothelial Nos3 knockdown CKO mice and MnTMPyP-treated CKO mice. The medial thickness was less affected in these mice, which is consistent with the markedly reduced but still elevated RVSP. Together, our data demonstrate that endothelial Cav1 deficiency secondary to PHD2 deficiency mediates the augmentation of nitrative stress in CKO mouse lungs via activation of endothelial Nos3, which leads to obliterative pulmonary vascular lesions and severe PH.

The current studies demonstrate that treatment with the ROS/RNS scavenger MnTMPyP attenuates both RVSP and vascular remodelling in CKO mice, which is consistent with a previous observation that antioxidant N-acetylcysteine treatment reduces PH induced by chronic hypoxia in rats [35]. However, another antioxidant, TEMPOL, has a beneficial effect on reducing RVSP but not arterial remodelling in the hypoxia and SU5416/hypoxia-induced PH rat model [36]. Thus, whether antioxidant therapies are effective in preclinical models of PH is still controversial, but this controversy might be due to the selected agents, doses and design of experiments [37]. For example, depending on the concentration and lung cell types, TEMPOL can be pro-oxidant or antioxidant [38]. Other studies also show that high concentrations of or extended exposure to TEMPOL increases ROS levels [39, 40]. Further studies are warranted to address this important question of whether antioxidants should be given to PAH patients for treatment of the disease.

In summary, we have demonstrated prominent nitrative stress in vascular lesions of CKO mice, which is mediated by endothelial Cav1 deficiency ascribed to HIF-2α activation and resultant eNOS activation. ROS/RNS scavenger treatment, CRISPR-mediated endothelial Nos3 knockdown or transgenic expression of Cav1 inhibit nitrative stress and obliterative pulmonary vascular remodelling and attenuate PH in CKO mice. Thus, Cav1 deficiency-induced oxidative/nitrative stress secondary to PHD2 deficiency is a part of the mechanism of severe PH in CKO mice, as seen in PAH patients.

MnTMPyP inhibited the PH seen in Cav1−/− mice, suggesting that chronic activation of eNOS secondary to Cav1 deficiency is the mechanism of PH induced by Cav1 deficiency [16]. Others have also shown that L-NAME treatment inhibits PH in Cav1−/− mice [33]. It has been shown that eNOS activation secondary to Cav1 deficiency leads to peroxynitrite formation, which causes PKG nitration in Cav1−/− mice. PKG nitration impairs its kinase activity and thereby induces pulmonary vascular remodelling and PH [16], eNOS activation and PKG nitration is prominent in lung tissues of IPAH patients [16, 34]. These studies provide unequivocal evidence that Cav1 deficiency induces nitrative stress, leading to PKG nitration and thus PH.

In summary, we have demonstrated prominent nitrative stress in vascular lesions of CKO mice, which is mediated by endothelial Cav1 deficiency ascribed to HIF-2α activation and resultant eNOS activation. ROS/RNS scavenger treatment, CRISPR-mediated endothelial Nos3 knockdown or transgenic expression of Cav1 inhibit nitrative stress and obliterative pulmonary vascular remodelling and attenuate PH in CKO mice. Thus, Cav1 deficiency-induced oxidative/nitrative stress secondary to PHD2 deficiency is a part of the mechanism of severe PH in CKO mice, as seen in PAH patients.

Acknowledgement: We greatly appreciate William C. Sessa from the Departments of Pharmacology and Medicine at Yale School of Medicine for his generosity in providing us with the Cav1−/− mice.

Author contributions: Z. Dai and Y-Y. Zhao conceived the experiments. Z. Dai, B. Liu, D. Yi, J. Dai, N. Machireddy, D. Dong, K. Ramirez, Y. Peng and M.M. Zhu designed and carried out experiments, and analysed the data. Z. Dai, R. Vanderpool and Y-Y. Zhao analysed and interpreted the data. Z. Dai wrote the manuscript. Z. Dai and Y-Y. Zhao supervised the project and revised the manuscript. All authors approved the manuscript.

Conflict of interest: Y-Y. Zhao is the founder and chief scientific officer of MountView Therapeutics LLC. This project utilises technologies subject to the following pending patents entitled “PLGA-PEG nanoparticles and
methods of uses” and “Cationic polymer-formulated nanoparticles and methods of use” to Y-Y. Zhao. The other authors declare no conflicts of interest.

Support statement: This work was supported in part by National Institutes of Health (NIH) (grants R01HL133951, R01HL140409, R01HL148810 and R01HL164014) to Y-Y. Zhao, and by NIH (R00HL13827 and R01HL158596), AHA Career Development Award (20CDAS3510084), ATS Foundation Pulmonary Hypertension Association Research Fellowship, Arizona Biomedical Research Center (ADHS18-198871) and the University of Arizona departmental start-up funding to Z. Dai. Funding information for this article has been deposited with the Crossref Funder Registry.

Reference
1  McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation 2009; 119: 2250–2294.
2  Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D42–D50.
3  Hautefort A, Mendes-Ferreira P, Sabourin J, et al. Bmpr2 mutant rats develop pulmonary and cardiac characteristics of pulmonary arterial hypertension. Circulation 2019; 139: 932–948.
4  Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 261–272.
5  Sutendra G, Michelakis ED. Pulmonary arterial hypertension: challenges in translational research and a vision for change. Sci Transl Med 2013; 5: 208sr5.
6  McLaughlin VV, Shah SJ, Souza R, et al. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65: 1976–1997.
7  Pullamsetti SS, Schermuly R, Ghofrani A, et al. Novel and emerging therapies for pulmonary hypertension. Am J Respir Crit Care Med 2014; 189: 394–400.
8  Spiekermann S, Schenk K, Hoeper MM. Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 34: 276.
9  Jankov RP, Kantores C, Pan J, et al. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Cell Mol Physiol 2008; 294: L233–L245.
10 Evans CE, Zhao Y-Y. Molecular basis of nitrative stress in the pathogenesis of pulmonary hypertension. Adv Exp Med Biol 2017; 967: 33–45.
11 Bowers R, Cool C, Murphy RC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004; 169: 764–769.
12 Masri FA, Comhair SAA, Dostanic-Larson I, et al. Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension. Clin Transl Sci 2008; 1: 99–106.
13 Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620–1624.
14 Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424–C1437.
15 Fulton D, Li X, Bordan Z, et al. Reactive oxygen and nitrogen species in the development of pulmonary hypertension. Antioxidants 2017; 6: 54.
16 Zhao Y-Y, Zhao YD, Mirza MK, et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest 2009; 119: 2009–2018.
17 Zhao Y-Y, Liu Y, Stan R-V, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA 2002; 99: 11375–11380.
18 Zhao YD, Cai L, Mirza MK, et al. Protein kinase G-I deficiency induces pulmonary hypertension through Rho A/ Rho kinase activation. Am J Pathol 2012; 180: 2268–2275.
19 Zhao Y-Y, Malik AB. A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. Trends Cardiovasc Med 2009; 19: 238–242.
20 Dai Z, Li M, Wharton J, et al. Prolyl-4 hydroxylase 2 (PHD2) deficiency in endothelial cells and hematopoietic cells induces obliterator vascular remodeling and severe pulmonary arterial hypertension in mice and humans through hypoxia-inducible factor-2a. Circulation 2016; 133: 2447–2458.
21 Dai Z, Zhao Y-Y. Discovery of a murine model of clinical PAH: mission impossible? Trends Cardiovasc Med 2017; 27: 229–236.
22 Bauer PM, Yu J, Chen Y, et al. Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc Natl Acad Sci USA 2005; 102: 204–209.
23 Murata T, Lin M, Huang Y, et al. Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J Exp Med 2007; 204: 2373–2382.
24 Yi D, Liu B, Wang T, et al. Endothelial autocrine signaling through ccr12/ccr4/foxm1 axis contributes to severe pulmonary arterial hypertension. Int J Mol Sci 2021; 22: 3182.
Dai Z, Zhu MM, Peng Y, et al. Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2α inhibitor. Am J Respir Crit Care Med 2018; 198: 1423–1434.

Dai Z, Zhu MM, Peng Y, et al. Endothelial and smooth muscle cell interaction via FoxM1 signaling mediates vascular remodeling and pulmonary hypertension. Am J Respir Crit Care Med 2018; 198: 788–802.

Zhang X, Jin H, Huang X, et al. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA. Cell Rep 2022; 38: 110196.

Peng YJ, Yuan G, Ramakrishnan D, et al. Heterozygous HIF-1α deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006; 577: 705–716.

Achcar ROD, Demura Y, Rai PR, et al. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006; 129: 696–705.

Mathew R, Huang J, Shah M, et al. Disruption of endothelial-cell caveolin-1/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004; 110: 1499–1506.

Oliveira SDS, Chen J, Castellon M, et al. Injury-induced shedding of extracellular vesicles depletes endothelial cells of Cav-1 (caveolin-1) and enables TGF-β (transforming growth factor-β)–dependent pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2019; 39: 1191–1202.

Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012; 5: 336–343.

Wunderlich C, Schmeisser A, Heerwagen C, et al. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulm Pharmacol Ther 2008; 21: 507–515.

Aggarwal S, Gross CM, Rafikov R, et al. Nitration of tyrosine 247 inhibits protein kinase G-1α activity by attenuating cyclic guanosine monophosphate binding. J Biol Chem 2014; 289: 7948–7961.

Hoshikawa Y, Ono S, Suzuki S, et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol (1985) 2001; 90: 1299–1306.

Voelkel NF, Bogaard HJ, Al HA, et al. Antioxidants for the treatment of patients with severe angioproliferative pulmonary hypertension? Antioxidants Redox Signal 2013; 18: 1810–1817.

Suzuki YJ, Steinhorn RH, Gladwin MT. Antioxidant therapy for the treatment of pulmonary hypertension. Antioxidants Redox Signal 2013; 18: 1723–1726.

Park WH. TEMPOL differently affects cellular redox changes and antioxidant enzymes in various lung-related cells. Sci Rep 2021; 11: 14869.

Han YH, Park WH. TEMPOL inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and apoptosis. Oncol Rep 2012; 27: 842–848.

Wang M, Li K, Zou Z, et al. Piperidine nitroxide tempol enhances cisplatin-induced apoptosis in ovarian cancer cells. Oncol Lett 2018; 16: 4847–4854.